Get started
Author

Federica Parodi

Observed names: F Parodi, Parodi, Federica
ORCID: 0000-0002-3048-2691
Observed ORCID: 0000-0002-3048-2691
OpenAlex ID: A5044203396
Tumor Origin of Endothelial Cells in Human Neuroblastoma
2007 · Annalisa Pezzolo, Federica Parodi, et al. · Journal of Clinical Oncology · 140
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
2015 · Barbara Banelli, Elisa Carra, et al. · Cell Cycle · 135
PDF
Endothelial and Smooth Muscle Cells from Abdominal Aortic Aneurysm Have Increased Oxidative Stress and Telomere Attrition
2012 · Giuseppe Cafueri, Federica Parodi, et al. · PLoS ONE · 108
PDF
Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells
2011 · Annalisa Pezzolo, Federica Parodi, et al. · Cell Research · 67
PDF
Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation
2016 · Federica Parodi, Roberta Carosio, et al. · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · 51
Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-γ
2006 · D Ribatti, B Nico, et al. · British Journal of Cancer · 46
PDF
A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2018 · Viktoryia Sidarovich, Marilena De Mariano, et al. · Molecular Cancer Therapeutics · 36
Short tandem repeat profiling for the authentication of cancer stem‐like cells
2020 · Paola Visconti, Federica Parodi, et al. · International Journal of Cancer · 32
PDF
Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma
2008 · Annalisa Pezzolo, Elena Rossi, et al. · Neuro-Oncology · 30
PDF
Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphoma
2021 · Giulio Donati, Micol Ravà, et al. · Molecular Oncology · 29
PDF
Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma
2008 · Annalisa Pezzolo, Valeria Capra, et al. · Cancer Letters · 24
A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma
2017 · Marilena De Mariano, Sara Stigliani, et al. · Oncotarget · 21
PDF
Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma
2016 · Adriana Amaro, Federica Parodi, et al. · JAMA Ophthalmology · 10
PDF
Identification of Novel Prognostic Markers in Relapsing Localized Resectable Neuroblastoma
2011 · Federica Parodi, Lorena Passoni, et al. · OMICS A Journal of Integrative Biology · 5
Loss of 10q26.1–q26.3 in association with 7q34–q36.3 gain or 17q24.3–q25.3 gain predict poor outcome in pediatric medulloblastoma
2011 · Annalisa Pezzolo, Simona Coco, et al. · Cancer Letters · 4
Chromosomal imbalances in pediatric Burkitt-like lymphoma and review of the literature in relation to other germinal center derived B-cell tumors
2006 · Annalisa Pezzolo, Roberta Cinti, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
1041 Real World Molecular Profiling in High-Grade Serous Ovarian Carcinoma: NGS for Homologous Recombination Deficiency Characterization
2026 · Federica Parodi, Andrea Vingiani, et al. · Laboratory Investigation
Supplementary Materials and Methods from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023 · Viktoryia Sidarovich, Marilena De Mariano, et al.
Supplementary Figure S3 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023 · Viktoryia Sidarovich, Marilena De Mariano, et al.
PDF
Supplementary Table 1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023 · Viktoryia Sidarovich, Marilena De Mariano, et al.
Supplementary Figure S2 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023 · Viktoryia Sidarovich, Marilena De Mariano, et al.
PDF
Supplementary Figure S4 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023 · Viktoryia Sidarovich, Marilena De Mariano, et al.
Data from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023 · Viktoryia Sidarovich, Marilena De Mariano, et al.
Supplementary Figure S1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023 · Viktoryia Sidarovich, Marilena De Mariano, et al.
PDF
Supplementary Table 1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023 · Viktoryia Sidarovich, Marilena De Mariano, et al.
Works count: 33
Citation count: 742
H-index: 12
I10-index: 13
Year
Topic
Type